Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid Tumors

PURPOSE: ENMD-2076 is a unique orally bioavailable Aurora kinase and VEGFR inhibitor. The purpose of this phase 1 study of ENMD-2076 was to determine the MTD, pharmacokinetic, and pharmacodynamic profiles and preliminary antitumor activity. EXPERIMENTAL DESIGN: Patients with refractory advanced soli...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Diamond, Jennifer R., Bastos, Bruno R., Hansen, Ryan J., Gustafson, Daniel L., Eckhardt, S. Gail, Kwak, Eunice L., Pandya, Shuchi S., Fletcher, Graham C., Pitts, Todd M., Kulikowski, Gillian N., Morrow, Mark, Arnott, Jamie, Bray, Mark R., Sidor, Carolyn, Messersmith, Wells, Shapiro, Geoffrey I.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3867298/
https://ncbi.nlm.nih.gov/pubmed/21131552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2144
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados